Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21 (APP21 Trial)
Recruiting in Palo Alto (17 mi)
Overseen ByDavid M Lubaroff, PhD
Age: 18+
Sex: Male
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: David M Lubaroff
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Androgen deprivation therapy (ADT) + Adenovirus/PSA VaccineExperimental Treatment1 Intervention
On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
Group II: Adenovirus/PSA VaccineExperimental Treatment1 Intervention
On Arm A, subjects can begin the three vaccinations immediately.
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Holden Comprehensive Cancer CenterIowa City, IA
Loading ...
Who is running the clinical trial?
David M LubaroffLead Sponsor
United States Department of DefenseCollaborator